DiaMedica Inc. (DiaMedica) is a development stage biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica�s product candidate includes DM-199 and DM-204. DM-199 is a recombinant human protein that represents a novel approach to treating Type I and Type II diabetes. The DM-199 program has demonstrated efficacy in three areas of Type I diabetes treatment; immune therapy, beta cell therapy and glucose control. DM-204 is a monoclonal antibody (mAb) that activates a G-protein coupled receptor (GPCR) for the treatment of Type II diabetes and other diseases. DiaMedica is initially focused on the treatment of diabetes and some of the associated major complications, including blood pressure and cholesterol. Chronic treatment with DM-204 in a Type II diabetes model resulted in improvement in blood glucose control and glycosylated hemoglobin (HbA1c) levels and also decreases in blood pressure and serum cholesterol.